APA (7th ed.) Citation

JS, H., X, Z., K, R., A, B., & S, L. (2025). Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial. Eye (London, England). https://doi.org/10.1038/s41433-024-03543-x

Chicago Style (17th ed.) Citation

JS, Heier, Zhang X, Reed K, Berliner A, and Leal S. "Infographic: Efficacy and Safety of High-dose Intravitreal Aflibercept 8 mg in Patients with Neovascular Age-related Macular Degeneration: Week 48 Results from the Phase 3 PULSAR Trial." Eye (London, England) 2025. https://doi.org/10.1038/s41433-024-03543-x.

MLA (9th ed.) Citation

JS, Heier, et al. "Infographic: Efficacy and Safety of High-dose Intravitreal Aflibercept 8 mg in Patients with Neovascular Age-related Macular Degeneration: Week 48 Results from the Phase 3 PULSAR Trial." Eye (London, England), 2025, https://doi.org/10.1038/s41433-024-03543-x.